B+
Bull case
25%
Probability
Target price
$14.00
+102.9% vs current
AURA
Aura BiosciencesANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$8.00
+15.9% vs current
B-
Bear case
30%
Probability
Target price
$3.50
-49.3% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+67.2
Score
AI commentary
Sentiment is cautiously constructive but still monitoring-oriented. The March 30 primary-source update improved milestone visibility and reaffirmed runway into Q1 2027, yet the deterministic prior remains negative and the highest-value catalyst is still the 2H 2027 CoMpass topline event [#8-K-2026-03-30]. That leaves AURA as an event-driven small-cap biotech where nearer-term 2026 data can help sentiment, but conviction should stay moderate rather than fully bullish [#10-K-2026-03-30].
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30eventPhase 3 CoMpass enrollment completion targeted for mid-2026High impact
Management said accelerated Phase 3 CoMpass enrollment supports enrollment completion by mid-2026; hitting that mark would reduce execution risk and support the current registration path under the FDA SPA framework [#8-K-2026-03-30].
2026-07-15catalystInitial 3-month NMIBC clinical data expected mid-2026High impact
Aura said its Phase 1b/2 NMIBC trial remains on track with initial 3-month clinical data expected in mid-2026, making this the nearest material proof-point for bel-sar outside ocular oncology [#8-K-2026-03-30].
2027-10-01catalyst2H 2027 topline data from Phase 3 CoMpass remains the main value driverHigh impact
The March 30 update points to second-half 2027 topline data for the 15-month primary endpoint in CoMpass, which remains the core rerating event for the equity but is still far enough out to keep the story in monitoring mode [#8-K-2026-03-30].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology